Used in the treatment of Parkinson’s disease, rasagiline mesylate helps improve motor function by inhibiting the breakdown of dopamine in the brain. It is a selective monoamine oxidase-B (MAO-B) inhibitor, which increases dopamine levels, reducing symptoms such as tremors, stiffness, and slowness of movement. Often used as monotherapy in early-stage Parkinson’s or as an adjunct to levodopa in more advanced cases, it helps reduce "off" periods when medication effects wear off. The drug offers neuroprotective potential in preclinical studies, though clinical significance remains under investigation. Its once-daily dosing improves patient compliance and provides consistent symptom control throughout the day.